Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this result using insurance claims data. They found that semaglutide and tirzepatide—marketed as Ozempic and Mounjaro—reduced the risk of serious cardiovascular events by up to 18%.
This article was originally published on MedicalXpress.com
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
Do you want to know more about attachment types and adult relationships? If so, you’ve come to the right place! In this blog, we’ll examine how different attachment styles impact our relationships and how understanding […]
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
© 2025 SimplyWell.ca